Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Trius closes $30mm Series B round led by KPCB

Executive Summary

Trius Therapeutics (antibacterials) raised $30mm in its Series B financing round led by first-time investor Kleiner, Perkins, Caufield & Byers, which contributes a member to the company's board. Other new backer FinTech Global Capital was joined by Series A shareholders Sofinnova Ventures, Versant Ventures, Interwest Partners, and Prism VentureWorks. Trius will use the money to move its oxazolidinone antibacterial compound TR701 through Phase II clinical trials.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies